IBI354, an anti-HER2 monoclonal antibody-camptothecin derivative conjugate, has shown good anti-tumor activity in platinum-resistant ovarian cancer with HER2 expression of 1+. In our Phase 1 study ...

Scientists have identified a promising new target for cancer treatment by activating a DNA repair enzyme called TDP1, ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.

The breakthrough research was conducted by scientists at the Indian Association for the Cultivation of Science (IACS), ...

In a promising development for cancer treatment, researchers have pinpointed a new target by activating a DNA repair enzyme ...

VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation ...

Innovent Biologics Inc. unveiled for the first time safety and efficacy data of IBI-354, an HER2 monoclonal antibody-camptothecin derivative conjugate that shows promising efficacy signals across a ...

Last year, it also revived a collaboration with ImmunoGen, more than a decade after backing away from a relationship, to claim an interest in its camptothecin payload technology. That deal ...

Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates Camptothecins are increasingly preferred payloads for antibody-drug conjugates (ADCs). In this manuscript, ...

The anti-tumour effects of Berberine, which possesses multiple pharmacological activities, have gained significant attention ...